News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PharmaEngine, Inc. Announces Achieving Patient Enrollment Goal in the Phase III Metastatic Pancreatic Cancer Study of PEP02 (MM-398)



8/29/2013 10:14:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. (TWO:4162) announced today that together with PharmaEngine’s partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), we reach the goal of patient enrollment in the global phase 3 metastatic pancreatic cancer study of PEP02 (MM-398). The total target number of patient enrollment is 405. The first patient received the first dose of MM-398 in January 2012.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES